AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3147048
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose theophylline (10-15 mg/l)
Trial: 3147048
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose theophylline (15-20 mg/l)
Trial: 27350068
Drug: Tabalumab 100
RxNorm normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabalumab 100 mg + Dexamethasone 20 mg/day + Bortezomib 1.3 mg/m² (Cohort 1)
Trial: 27350068
Drug: Tabalumab 300
RxNorm normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabalumab 300 mg + Dexamethasone 20 mg/day + Bortezomib 1.3 mg/m² (Cohort 2)
Trial: 27350068
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Tabalumab 100 mg or 300 mg + Dexamethasone + Bortezomib)
Trial: 26276751
Drug: Soy bread
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy bread (34 mg isoflavones/slice)
Trial: 22976766
Drug: Enzyme replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme replacement therapy (ERT) with imiglucerase
Trial: 12800782
Drug: Nasal CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal CPAP treatment
Trial: 12800782
Drug: Placebo-controlled treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-controlled treatment trials
Trial: 31809622
Drug: Androgen receptor
RxNorm normalized name: Androgen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen receptor splice variant 7 (AR‐V7) mRNA expression in hormone-sensitive prostate cancer (HSPC) and castration-resistant prostate cancer (CRPC)
Trial: 29405668
Drug: Meloxicam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (10 mg in 10 mL saline)
Trial: 24337625
Drug: CIK treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIK treatment plus standard treatment
Trial: 20823097
Drug: Rolofylline 30
RxNorm normalized name: Rolofylline
DrugBank: Rolofylline (DB12670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rolofylline 30 mg administered as a 4 h infusion
Trial: 11443569
Drug: Nitazoxanide 500‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide 500‐mg tablet twice daily for 3 days
Trial: 31728675
Drug: Single standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single standard dose of sucrose 2 min before heel prick
Trial: 31728675
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of sucrose 2 min before and 30 s after heel prick
Trial: 27312122
Drug: Oral product
RxNorm normalized name: Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral product alone (ZO-1)
Trial: 27312122
Drug: Oral product
RxNorm normalized name: Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral product with topical product (ZO-2 + ZT)
Trial: 27312122
Drug: Combination active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination active groups (ZO-2 + ZT)
Trial: 27312122
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement alone (ZO-1)
Trial: 18754720
Drug: Prophylactic low-level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic low-level laser therapy (LLLT)
Trial: 18754720
Drug: Therapeutic low-level
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic low-level laser therapy (LLLT)
Trial: 17056950
Drug: Paracetamol 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1000 mg IV
Trial: 14616463
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice (500 mL diluted with 1500 mL tap water for 2 weeks)
Trial: 14616463
Drug: Tap water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tap water (2000 mL for 2 weeks)
Trial: 16344024
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of oxymorphone immediate release (IR)
Trial: 2117625
Drug: Ribavirin 1200
RxNorm normalized name: ribavirin 1200 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin 1200 mg
Trial: 2117625
Drug: Ribavirin 1600
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin 1600 mg
Trial: 6452805
Drug: Zimelidine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine (100 mg at night, increasing to 200 mg after two weeks)
Trial: 6452805
Drug: Amitriptyline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (75 mg at night, increasing to 150 mg after two weeks)
Trial: 31604060
Drug: Low-Level Laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Level Laser Therapy (LLLT) applied at 5 intraoral points for 30 seconds each on one side (laser group)
Trial: 26507618
Drug: Fixed-Dose Combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-Dose Combination (FDC) of aspirin and clopidogrel
Trial: 26507618
Drug: Separate Dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate Dual Pills (SDP) of aspirin and clopidogrel
Trial: 21559284
Drug: Intravenous GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GH bolus plus an oral glucose load (OGTT)
Trial: 21559284
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline plus OGTT
Trial: 19264678
Drug: Imatinib <350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib <350 mg daily
Trial: 11240262
Drug: Five-field segmented
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-field segmented irradiation technique with a planned dose of 78 Gy.
Trial: 31081504
Drug: Nintendo WiiFit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintendo WiiFit balance training, conducted twice a week for 3 months.
Trial: 23564361
Drug: Manual circumlaryngeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual circumlaryngeal therapy for 20 minutes
Trial: 8551476
Drug: Amnioinfusion (300-500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amnioinfusion (300-500 mL bolus and 125-150 mL/h constant drip)
Trial: 1699835
Drug: IV albumin
RxNorm normalized name: albumin human, USP Injection [Albuminar]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV albumin (8 g/L of ascitic fluid removed)
Trial: 1699835
Drug: IV dextran-70
RxNorm normalized name: Dextran 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dextran-70 (8 g/L of ascitic fluid removed)
Trial: 507789
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and probenecid
Trial: 29489484
Drug: 800-kcal, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800-kcal, 20 g fat, and 70 g protein diet for 1 week before liver resection
Trial: 26121998
Drug: Telephone-delivered multiple
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-delivered multiple health behaviour change intervention using acceptance commitment therapy strategies
Trial: 26121998
Drug: Health professional
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health professional visits and medications
Trial: 21482566
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil 600 mg iv every 12 h
Trial: 21482566
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g iv every 24 h
Trial: 16398939
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC 5) plus paclitaxel (175 mg/m2) every 3 weeks for 6 cycles
Trial: 3427552
Drug: Prenylamine (PNL)
RxNorm normalized name: prenylamine
DrugBank: Prenylamine (DB04825)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenylamine (PNL) 200 mg/day
Trial: 3427552
Drug: Adriamycin (ADM)
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin (ADM) at standard oncological doses up to 550 mg/m2 plus placebo
Trial: 11467701
Drug: Mifepristone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 50 mg followed by gemeprost 0.5 mg
Trial: 11467701
Drug: Mifepristone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 50 mg followed by gemeprost 1.0 mg
Trial: 11467701
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg followed by gemeprost 0.5 mg
Trial: 11467701
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg followed by gemeprost 1.0 mg
Trial: 2638181
Drug: Triclosan/zinc formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triclosan/zinc formulations
Trial: 28118272
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs for 10 days (same for both groups)
Trial: 23608246
Drug: Cabergoline starting
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline starting on the day of HCG injection
Trial: 21279990
Drug: R788 (fostamatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R788 (fostamatinib disodium) 100 mg twice daily
Trial: 18640170
Drug: HPV 16
RxNorm normalized name: HPV 16 E7/HSP65 vaccine
DrugBank: Verpasep caltespen (DB04959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV 16 and 18 vaccine (3 doses)
Trial: 14641395
Drug: Nurse telephone
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse telephone calls intervention applied for 12 weeks, consisting of education and reinforcement of diet, exercise, medication adjustment recommendations, and self-monitoring of blood glucose levels.
Trial: 9241127
Drug: Intermittent etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent etidronate (400 mg per day for 14 days) followed by calcium (500 mg per day for 76 days), given for four cycles
Trial: 3524231
Drug: mazindol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mazindol (2 mg daily)
Trial: 1889143
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg pirenzepine
Trial: 1889143
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg pirenzepine at night
Trial: 3902672
Drug: Timolol 20
RxNorm normalized name: timolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 20 mg once daily
Trial: 27784751
Drug: Adjunctive brexpiprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive brexpiprazole
Trial: 20189174
Drug: Zhibitai (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhibitai (480 mg orally twice daily)
Trial: 20189174
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg orally once a day)
Trial: 20189174
Drug: Both Zhibitai
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Zhibitai and Atorvastatin
Trial: 15497510
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin (n=10)
Trial: 8313183
Drug: Dihydroartemisinin (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin (360 mg in 5 days and 480 mg in 7 days)
Trial: 31122494
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with cilostazol (100 mg, twice per day) and aspirin or clopidogrel
Trial: 31122494
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with aspirin (81 or 100 mg, once per day) or clopidogrel (50 or 75 mg, once per day)
Trial: 25134047
Drug: Prescription group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription group (n = 32) given a take-home supply of oral naltrexone
Trial: 21716267
Drug: S-ketamine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine (0.2 mg/kg) after pretreatment with ticlopidine (250 mg twice daily)
Trial: 21716267
Drug: S-ketamine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine (0.2 mg/kg) after pretreatment with itraconazole (200 mg once daily)
Trial: 16833023
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg risperidone tablet
Trial: 8096475
Drug: 5% glucose
RxNorm normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glucose infusion
Trial: 11048829
Drug: No glucose
RxNorm normalized name: No glucose hemofiltration solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No glucose infusion (control)
Trial: 22209361
Drug: Lu AA21004
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu AA21004 10 mg
Trial: 22901346
Drug: Lu AA21004
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu AA21004 1 mg
Trial: 22209361
Drug: Lu AA21004
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu AA21004 5 mg
Trial: 20445497
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral sodium bicarbonate
Trial: 9715485
Drug: Topical prednisolone
RxNorm normalized name: prednisolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prednisolone acetate
Trial: 27063162
Drug: Intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive statin therapy (atorvastatin, 80 mg/day, 3 days before till 3 days after intervention)
Trial: 27063162
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (atorvastatin, 20 mg/day)
Trial: 23185751
Drug: CMM +
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CMM + chemotherapy (189 cases)
Trial: 23185751
Drug: Chemotherapy (177
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (177 cases)
Trial: 20400920
Drug: Target-controlled infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-controlled infusion (TCI) of remifentanil (0.8 ng · mL as effect-site target)
Trial: 20400920
Drug: Manually controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manually controlled infusion of remifentanil (loading dose of 0.75 μg · kg and 0.075 μg · kg · min as maintenance)
Trial: 16261287
Drug: MCC-135 (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCC-135 (4.5 mg/kg/48 hours)
Trial: 16261287
Drug: MCC-135 (9.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCC-135 (9.0 mg/kg/48 hours)
Trial: 16261287
Drug: MCC-135 (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCC-135 (4.5 mg/kg/48 hours) and MCC-135 (9.0 mg/kg/48 hours)
Trial: 12239666
Drug: Collagenase injection
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Collagenase injection therapy (one dose)
Trial: 12239666
Drug: Collagenase injection
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Collagenase injection therapy (dose-response study)
Trial: 10665619
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT), delivered in 19 individual sessions over 9 months
Trial: 8842506
Drug: Propafenone 300
RxNorm normalized name: propafenone 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone 300 mg tid
Trial: 8842506
Drug: Disopyramide 250
RxNorm normalized name: disopyramide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide 250 mg tid
Trial: 6508975
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal 25 g administered 5 min after drug ingestion on an empty stomach
Trial: 6508975
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal 25 g administered 60 min after drug ingestion on an empty stomach
Trial: 6508975
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal 25 g administered 5 min after drug ingestion after a standard meal
Trial: 6508975
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal 25 g administered 60 min after drug ingestion after a standard meal
Trial: 30753449
Drug: CPR-retraining based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPR-retraining based on hands-on rolling refreshers during the 2-month program (G-CPR, n = 53)
Trial: 30753449
Drug: Standard one-time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard one-time training (G-Stan, n = 61)
Trial: 30753449
Drug: CPR-retraining (G-CPR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPR-retraining (G-CPR)
Trial: 25352865
Drug: 10% IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% IV dextrose infusion by burettes
Trial: 16024305
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily for 4-8 weeks
Trial: 16024305
Drug: Maintenance with
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance with rabeprazole 10 mg or 2x10 mg once daily for a maximum of 48 weeks
Trial: 9384841
Drug: Gradual discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual discontinuation of lithium
Trial: 9384841
Drug: Sharp reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sharp reduction in lithium dose
Trial: 9384841
Drug: Other disorders
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other disorders and treatments (neuroleptics in schizophrenia, antidepressants in recurrent depression)
Trial: 3711599
Drug: High fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fat breakfast followed by iv injection of 1000 u heparin (high NEFA protocol)
Trial: 28635634
Drug: 4 +
RxNorm normalized name: MK-4 + MK-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 + 4 g/day oral EAAs
Trial: 26233286
Drug: Decorated objects
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decorated objects (e.g., polka dots, feathers)
Trial: 21210776
Drug: Berlin-Frankfürt-Münster-derived acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berlin-Frankfürt-Münster-derived acute lymphoblastic leukaemia (ALL) therapy
Trial: 17243596
Drug: G‐Bond (GBO,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐Bond (GBO, GC)
Trial: 15504183
Drug: Rocuronium 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.03 mg kg(‐1)
Trial: 11549539
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (250 mg of vitamin C, 50 IU of alpha-tocopherol, and 12 oz of vegetable cocktail daily for 2 weeks)
Trial: 9029389
Drug: Cefazolin administered
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin administered preoperatively (1 g)
Trial: 9029389
Drug: Cefazolin administered
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin administered after cord clamping (1 g)
Trial: 8299661
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg once a day
Trial: 30548375
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for psychosis (CBTp) or Metacognition‐Oriented Social Skills training